Table 5.
Emergent Resistance in Maraviroc Switch Study Participants With Confirmed Virological Failure Over 48 Weeks
| Study Arm | Confirmed Virological Failure | Viral Load at Viral Failure, Copies/mL | Country of Enrollment | PI and RT Sequencing Results | Tropism (Phenotypic Assessment) at Viral Failure |
|---|---|---|---|---|---|
| Control | Week 36 | 2280.0 | Argentina | K103KN | CCR5 |
| MVC + 2 N(t)RTIs | Week 12 | 7248.0 | Argentina | M41L, T215E | CCR5 |
| MVC + 2 N(t)RTIs | Week 12 | 55 808.0 | Mexico | M184V, K101E, Y181C, G190A | CCR5 |
| MVC + 2 N(t)RTIs | Week 12 | 2810.0 | Germany | L10I, K65R; V106I | Test failed |
| MVC + 2 N(t)RTIs | Week 36 | 4812.0 | Spain | L10I, A71V, M184V | CCR5 |
| MVC + 2 N(t)RTIs | Week 12 | 1133.0 | Poland | L90M, L10I, A71V, M184MV | CCR5 |
| MVC + PI/r | Week 48 | 891.0 | Argentina | None | CCR5 |
| MVC + PI/r | Week 48 | 730.0 | Argentina | L10I | Test failed |
| MVC + PI/r | Week 24 | 60 800.0 | Argentina | I50V, L10I, L33FL | CXCR4 |
| MVC + PI/r | Week 4 | 30 600.0 | Argentina | None | CCR5 |
| MVC + PI/r | Week 36 | 111 941.0 | Chile | None | CXCR4 |
| MVC + PI/r | Week 12 | 1157.0 | Mexico | None | CCR5 |
| MVC + PI/r | Week 36 | 5565.0 | Mexico | A62V, T215S | CCR5 |
| MVC + PI/r | Week 48 | 63 140.0 | Mexico | None | CXCR4 |
| MVC + PI/r | Week 48 | 5935.0 | Canada | None | CCR5 |
| MVC + PI/r | Week 36 | 1200.0 | Germany | K20I | Test failed |
| MVC + PI/r | Week 12 | 2208.0 | Germany | None | CCR5 |
| MVC + PI/r | Week 12 | 45 600.0 | Germany | None | CCR5 |
| MVC + PI/r | Week 12 | 2275.0 | Germany | E138A | CCR5 |
| MVC + PI/r | Week 12 | 545.0 | Poland | V32AV | Test failed |
| MVC + PI/r | Week 12 | 1924.0 | Poland | None | Test failed |
| MVC + PI/r | Week 36 | 2264.0 | Poland | None | CCR5 |
| MVC + PI/r | Week 48 | 821.0 | Poland | L10I | CCR5 |
Mutations highlighted in bold are major mutations of PI and RT (nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor).
Abbreviations: MVC, maraviroc; N(t)RTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor; RT, reverse transcriptase.